Communiqués Alector, Inc.

Actions

ALEC

US0144421072

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 21/08/2026			Varia. 5j.	Varia. 1 janv.
2,360 ^USD	+4,42 %		+20,41 %	+51,28 %

06/08	Alector, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
09/07	GSK nomme Roy Jakobs, PDG de Royal Philips, à son conseil d'administration	AN

Communiqués

07/08	Alector : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)	PU
06/08	Alector: Q2 Earnings Snapshot	AQ
06/08	Alector Reports Second Quarter 2026 Financial Results and Provides Business Update	GL
08/05	Alector : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	Alector: Q1 Earnings Snapshot	AQ
07/05	Alector Reports First Quarter 2026 Financial Results and Provides Business Update	GL
29/04	Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis	GL
25/03	Alector : March 2026 Corporate Presentation	PU
25/02	Alector : February 2026 Corporate Presentation	PU
25/02	Alector: Q4 Earnings Snapshot	AQ
25/02	Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update	GL
24/02	Alector to Participate in the TD Cowen 46th Annual Health Care Conference	GL
03/02	Alector : February 2026 Update	PU
30/01	Levi & Korsinsky is Investigating Alec Stock After its Phase 3 INFRONT-3 Clinical Trial Misses Co-Primary Endpoint	PR
07/01	Alector : January 2026 Corporate Presentation	PU
12/12	Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer	GL
01/12	Alector to Participate in the Bank of America CNS Therapeutics Conference	GL
06/11	Alector : November 2025 Corporate Presentation	PU
06/11	Alector: Q3 Earnings Snapshot	AQ
06/11	Alector Reports Third Quarter 2025 Financial Results and Provides Business Update	GL
06/11	Alector Reports Third Quarter 2025 Financial Results and Provides Business Update	AQ
21/10/25	Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update	GL
21/10/25	Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update	AQ
23/09/25	Alector R&D Briefing: A Review of Our PGRN Franchise and Brain Carrier Programs	PU
16/09/25	Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs	GL